V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Emergent BioSolutions Executive Compensation (FY25)

EBS · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Joseph Papa
Latest say-on-pay support
=
April 29, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The Emergent BioSolutions brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
Data as of October 18, 2026Latest filing (8-K): April 30, 2026
15 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Emergent BioSolutions brief$1,500Get the executive brief
Velarion Member, one year
342 figures on this page: 324 cited to the filing that reported them, 18 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Joseph Papa: $5,862,562 → $5,321,147 (9.2% lower)
Say-on-pay support: 84.3% → 60.3% (24.0 points lower)
CEO pay ratio: 48:1 → 41:1 (14.6% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is Emergent BioSolutions' chief executive and what were they paid?
Total compensation for Joseph Papa, President, Chief Executive Officer and Director, came to $5,321,147 in fiscal 2025. Compared with the $5,862,562 reported for fiscal 2024, Papa's total was 9.2% lower.
What was Emergent BioSolutions' say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 60.3% of votes cast for or against in favor at the meeting held April 29, 2026.
Which companies are in Emergent BioSolutions' peer group?
The disclosed peer group includes ACADIA Pharmaceuticals Inc., Alkermes plc, Amneal Pharmaceuticals, Inc., Amphastar Pharmaceuticals, Inc. and ANI Pharmaceuticals, Inc., among others.
What is Emergent BioSolutions' chief executive pay ratio?
The company reported a chief executive pay ratio of 41:1 for fiscal 2025, against median employee compensation of $130,553.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Robert Kramer
Former President, Chief Executive Officer and Director
◇—◇◇◇—◇◇
Adam Havey
Executive Vice President and Chief Operating Officer
◇—◇◇◇—◇◇
Richard Lindahl
Executive Vice President, Chief Financial Officer and Treasurer
◇—◇◇◇—◇◇
Jennifer Fox
Executive Vice President, External Affairs, General Counsel and Corporate Secretary
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Robert Kramer
Former President, Chief Executive Officer and Director
Departed during or after this year
◇—◇◇——◇◇
Richard Lindahl
Executive Vice President, Chief Financial Officer and Treasurer
◇◇◇◇——◇◇
Jennifer Fox
Executive Vice President, External Affairs, General Counsel and Corporate Secretary
◇◇◇◇——◇◇
Adam Havey
Executive Vice President and Chief Operating Officer
◇—◇◇——◇◇
Coleen Glessner
Executive Vice President, Quality and Ethics and Compliance
◇◇◇◇——◇◇
Paul Williams
Senior Vice President, Products Business
◇◇◇◇——◇◇
Haywood Miller
Interim Chief Executive Officer
◇——————◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Joseph Papa
President, Chief Executive Officer and Director
◇◇◇◇◇—◇◇
Richard Lindahl
Executive Vice President, Chief Financial Officer
◇◇◇◇◇—◇◇
Coleen Glessner
Executive Vice President, Quality and Ethics and Compliance
◇◇—◇◇—◇◇
William Hartzel
Senior Vice President, Manufacturing and Bioservices
◇◇◇◇◇—◇◇
Paul Williams
Senior Vice President, Products Business
◇◇—◇◇—◇◇
Jennifer Fox
Former Executive Vice President, External Affairs, General Counsel and Corporate Secretary
Departed during or after this year
◇◇◇◇——◇◇
Haywood Miller
Former Interim Chief Executive Officer
Departed during or after this year
◇——————◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Joseph Papa
President, Chief Executive Officer and Director
◇—◇◇◇—◇◇
Richard Lindahl
Executive Vice President, Chief Financial Officer
◇—◇◇◇—◇◇
Coleen Glessner
Executive Vice President, Quality and Ethics and Compliance
◇—◇◇◇—◇◇
Simon Lowry
Chief Medical Officer, Head of Research and Development
◇—◇◇◇—◇◇
Paul Williams
Senior Vice President, Products Business
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Coleen GlessnerRSU◇——◇——◇
Joseph PapaPSU◇◇◇———◇
Paul WilliamsRSU◇——◇——◇
Richard LindahlRSU◇——◇——◇
Simon LowryRSU◇——◇——◇
Fiscal 2023 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Joseph PapaRSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Richard LindahlRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Coleen GlessnerRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇—
RSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
Simon LowryRSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
Paul WilliamsRSU◇◇——
RSU◇=——
RSU◇=——
RSU◇◇——
RSU◇=——
RSU◇=——
RSU◇=——
RSU◇◇——
RSU◇=——
RSU◇=——
RSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Coleen Glessner
Executive Vice President, Quality and Ethics and Compliance · Severance agreement
Equity acceleration on change in control◇
Excise tax treatment◇
Non-compete period◇
Non-solicit period◇
Clawback◇
Joseph Papa
President, Chief Executive Officer and Director · Severance agreement
Equity acceleration on change in control◇
Excise tax treatment◇
Non-compete period◇
Non-solicit period◇
Clawback◇
Paul Williams
Senior Vice President, Products Business · Severance agreement
Equity acceleration on change in control◇
Non-compete period◇
Non-solicit period◇
Clawback◇
Richard Lindahl
Executive Vice President, Chief Financial Officer · Severance agreement
Equity acceleration on change in control◇
Non-compete period◇
Non-solicit period◇
Clawback◇
Simon Lowry
Chief Medical Officer, Head of Research and Development · Severance agreement
Equity acceleration on change in control◇
Excise tax treatment◇
Non-compete period◇
Non-solicit period◇
Clawback◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Zsolt Harsanyi, Ph.D
Board chair
◇◇————◇
Marvin White
◇◇————◇
Kathryn Zoon, Ph.D
◇◇————◇
Keith Katkin
◇◇————◇
Ronald Richard
◇◇————◇
Sujata Dayal
◇◇————◇
Neal Fowler
◇◇————◇
Louis Sullivan, M.D
◇◇————◇
Donald DeGolyer
◇◇————◇
John Fowler Jr and Joseph Papa served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as 75% RSUs and 25% stock options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • ACADIA Pharmaceuticals Inc. ACAD
  • Alkermes plc ALKS
  • Amneal Pharmaceuticals, Inc. AMRX
  • Amphastar Pharmaceuticals, Inc. AMPH
  • ANI Pharmaceuticals, Inc. ANIP
  • Collegium Pharmaceutical, Inc. COLL
  • CRISPR Therapeutics AG CRSP
  • Dynavax Technologies Corporation DVAX
  • Haemonetics Corporation HAE
  • Integra LifeSciences Holdings Corporation IART
  • Ionis Pharmaceuticals, Inc. IONS
  • Myriad Genetics, Inc. MYGN
  • OPKO Health, Inc. OPK
  • Pacira BioSciences, Inc. PCRX
  • PTC Therapeutics, Inc. PTCT
  • Supernus Pharmaceuticals, Inc. SUPN

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025April 29, 2026=◇◇◇
2024April 30, 2025=◇◇◇
2023May 23, 2024=◇◇◇
2022May 25, 2023=◇◇◇
2021May 26, 2022=◇◇◇
2020May 20, 2021=◇◇◇
2019May 21, 2020=◇◇◇
2018May 23, 2019=◇◇◇
2017May 24, 2018=◇◇◇
2016May 25, 2017=◇◇◇
2015May 19, 2016=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Joseph Papa (President, Chief Executive Officer and Director), FY2025 total compensation $5,321,147 (base salary $1,037,385) [exec_comp, SEC accession 0001367644-26-000033, filed 2026-03-20]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Emergent BioSolutions files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Emergent BioSolutions disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Emergent BioSolutions sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Say-on-pay responsiveness
Emergent BioSolutions recorded a low support level. The responsiveness analysis covers what the company said it would do, what it did, and how that compares with the companies that recovered their vote.
Responsiveness analysis
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Emergent BioSolutions' disclosed peer group is defensible, who names Emergent BioSolutions back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
342 figures on this page: 324 cited to the filing that reported them, 18 calculated from figures it prints.
324 cited to the filing
18 calculated from the filing

Documents cited

  1. 0001367644-26-000051
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001367644-26-000033
    2025 Summary Compensation Table · CEO Pay Ratio Disclosure · Director Compensation · Grants of Plan-Based Awards · and 2 more sections
  3. 0001367644-25-000114
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001367644-25-000080
    2024 Summary Compensation Table · Summary Compensation Table
  5. 0001367644-24-000093
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0001193125-24-093400
    2023 Summary Compensation Table
  7. 0001367644-23-000112
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0001367644-22-000080
    Item 5.07 Submission of Matters to a Vote of Security Holders
  9. 0001367644-21-000099
    Item 5.07 Submission of Matters to a Vote of Security Holders
  10. 0001367644-20-000082
    Item 5.07 Submission of Matters to a Vote of Security Holders
  11. 0001367644-19-000027
    Item 5.07 Submission of Matters to a Vote of Security Holders
  12. 0001367644-18-000025
    Item 5.07 Submission of Matters to a Vote of Security Holders
  13. 0001367644-17-000024
    Item 5.07 Submission of Matters to a Vote of Security Holders
  14. 0001367644-16-000066
    Item 5.07 Submission of Matters to a Vote of Security Holders
  15. 0001367644-15-000033
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Emergent BioSolutions executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/EBS (accessed 2026).
Short form: data: Velarion

The Emergent BioSolutions brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
15 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Emergent BioSolutions and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Emergent BioSolutions discloses

The companies named in EBS's own disclosed peer group.

ACADIA Pharmaceuticals Inc.Alkermes plcAmneal Pharmaceuticals, Inc.Amphastar Pharmaceuticals, Inc.ANI Pharmaceuticals, Inc.Collegium Pharmaceutical, Inc.CRISPR Therapeutics AGDynavax Technologies CorporationHaemonetics CorporationIntegra LifeSciences Holdings CorporationIonis Pharmaceuticals, Inc.Myriad Genetics, Inc.OPKO Health, Inc.Pacira BioSciences, Inc.PTC Therapeutics, Inc.Supernus Pharmaceuticals, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy